Form 4 for ORKA Oruka Therapeutics, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-16 · accession 0000907654-26-000030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-17 | 2026-03-16 | ORKA | Goncalves Joana | Chief Medical Off | S - Sale+OE | $40.91 | -7,641 | 33.4K | -19% | -$312.6K |
| DM | 2026-03-17 | 2026-03-16 | ORKA | Goncalves Joana | Chief Medical Off | M - OptEx | $7.32 | +7,000 | 37.5K | +23% | +$51.2K |
| DM | 2026-03-17 | 2026-03-16 | ORKA | Goncalves Joana | Chief Medical Off | M - OptEx | $0.00 | -7,000 | 214.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-16 | S | D | 1,177 | $41.94 | 34,018 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.75 to $42.28, inclusive. |
| 2 | Common | Common Stock | 2026-03-16 | S | D | 2,902 | $41.20 | 35,195 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.70, inclusive. |
| 3 | Common | Common Stock | 2026-03-16 | S | D | 2,921 | $40.11 | 38,097 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.64, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. |
| 4 | Common | Common Stock | 2026-03-16 | M | A | 3,500 | $7.80 | 41,018 | D | — | — | |
| 5 | Common | Common Stock | 2026-03-16 | M | A | 3,500 | $6.84 | 37,518 | D | — | — | |
| 6 | Common | Common Stock | 2026-03-16 | S | D | 641 | $41.30 | 33,377 | D | — | — | |
| 7 | Derivative | Employee Warrant (right to buy) | 2026-03-16 | M | D | 3,500 | $0.00 | 185,992 | D | $7.80 · — to 2034-07-14 | 3,500 Common Stock | (F7) The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2026-03-16 | M | D | 3,500 | $0.00 | 214,563 | D | $6.84 · — to 2034-05-06 | 3,500 Common Stock | (F6) The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025. |